Citation: | LIAN Yanjie, LIU Zihao, LIU Hongxu, ZHANG Heyi, SHANG Juju, LAI Xiaolei. Research hotspot and development trend of cellular burial in atherosclerosis analyzed based on Web of Science[J]. Chinese Journal of General Practice, 2024, 22(1): 148-153. doi: 10.16766/j.cnki.issn.1674-4152.003352 |
[1] |
中华医学会老年医学分会老年神经病学组, 北京神经科学学会血管神经病学专业委员会, 动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识编写组. 动脉粥样硬化性缺血性卒中/短暂性脑缺血发作合并冠心病诊治中国专家共识(2022)[J]. 中华医学杂志, 2022, 102(45): 3569-3580.
Geriatric Neurology Group of Geriatrics Branch of Chinese Medical Association, Vascular Neurology Committee of Beijing Neuroscience Society, Atherosclerotic Ischemic Stroke in Combination with Transient Ischemic Attack and Coronary Artery Disease Chinese Expert Consensus Writing Group. Chinese expert consensus on the diagnosis and management of atherosclerotic ischemic stroke/transient ischemic attack combined with coronary artery disease (2022)[J]. Chinese Journal of Medicine, 2022, 102(45): 3569-3580.
|
[2] |
汤紫薇, 谷依檬, 薛梅. 基于免疫炎症学说中医药防治动脉粥样硬化研究[J]. 中国中医基础医学杂志, 2022, 28(7): 1192-1198. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202207043.htm
TANG Z W, GU Y M, XUE M. Research on the prevention and treatment of atherosclerosis in Chinese medicine based on the immunoinflammatory theory[J]. Chinese Journal of Basic Chinese Medicine, 2022, 28(7): 1192-1198. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJC202207043.htm
|
[3] |
ZHANG W, ZHAO J, WANG R, et al. Macrophages reprogram after ischemic stroke and promote efferocytosis and inflammation resolution in the mouse brain[J]. CNS Neurosci Ther, 2019, 25(12): 1329-1342. doi: 10.1111/cns.13256
|
[4] |
ARANDJELOVIC S, RAVICHANDRAN K S. Phagocytosis of apoptotic cells in homeostasis[J]. Nat Immunol, 2015, 16(9): 907-917. doi: 10.1038/ni.3253
|
[5] |
TABAS I, GARCÍA-CARDEÑA G, OWENS G K. Recent insights into the cellular biology of atherosclerosis[J]. J Cell Biol, 2015, 209(1): 13-22. doi: 10.1083/jcb.201412052
|
[6] |
KOJIMA Y, VOLKMER J P, MCKENNA K, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis[J]. Nature, 2016, 536(7614): 86-90. doi: 10.1038/nature18935
|
[7] |
THORP E B. Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease[J]. Apoptosis, 2010, 15(9): 1124-1136. doi: 10.1007/s10495-010-0516-6
|
[8] |
陈悦, 刘则渊. 悄然兴起的科学知识图谱[J]. 科学学研究, 2005, 23(2): 149-154. https://www.cnki.com.cn/Article/CJFDTOTAL-KXYJ200502001.htm
CHEN Y, LIU Z Y. The quiet emergence of scientific knowledge mapping[J]. Scientific Research, 2005, 23(2): 149-154. https://www.cnki.com.cn/Article/CJFDTOTAL-KXYJ200502001.htm
|
[9] |
陈悦, 陈超美, 胡志刚. 引文空间分析原理与应用: CiteSpace实用指南[M]. 北京: 科学出版社, 2014: 10-20.
CHEN Y, CHEN C M, LIU Z Y, et al. Principles and applications of citation space analysis CiteSpace practical guide[M]. Beijing: Science Press, 2014: 10-20.
|
[10] |
AI Y, XING Y, YAN L, et al. Atrial fibrillation and depression: a bibliometric analysis from 2001 to 2021[J]. Front Cardiovasc Med, 2022, 9: 775329. DOI: 10.3389/fcvm.2022.775329.
|
[11] |
陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253. https://www.cnki.com.cn/Article/CJFDTOTAL-KXYJ201502009.htm
CHEN Y, CHEN C M, LIU Z Y, et al. Methodological functions of CiteSpace knowledge graphs[J]. Scientology Research, 2015, 33(2): 242-253. https://www.cnki.com.cn/Article/CJFDTOTAL-KXYJ201502009.htm
|
[12] |
NICHOLLS S J, PURI R, ANDERSON T, et al. Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial[J]. JAMA, 2016, 316(22): 2373-2384. doi: 10.1001/jama.2016.16951
|
[13] |
KOJIMA Y, WEISSMAN I L, LEEPER N J. The role of efferocytosis in atherosclerosis[J]. Circulation, 2017, 135(5): 476-489. doi: 10.1161/CIRCULATIONAHA.116.025684
|
[14] |
王烁珊, 吴敬国, 荆小莉, 等. 甘油三酯葡萄糖指数与冠状动脉粥样硬化性心脏病关系的研究进展[J]. 中华全科医学, 2021, 19(6): 1008-1012. doi: 10.16766/j.cnki.issn.1674-4152.001972
WANG S S, WU J G, JING X L, et al. Research progress on the relationship between triglyceride glucose index and coronary atherosclerotic heart disease[J]. Chinese Journal of General Practice, 2021, 19(6): 1008-1012. doi: 10.16766/j.cnki.issn.1674-4152.001972
|
[15] |
杨晓明, 王审. 长期大剂量服用阿托伐他汀对老年高血压合并冠心病的疗效和安全性评价[J]. 中华全科医学, 2018, 16(12): 2035-2038. doi: 10.16766/j.cnki.issn.1674-4152.000555
YANG X M, WANG S. . Evaluation of the efficacy and safety of long-term high-dose administration of atorvastatin in elderly with hypertension combined with coronary heart disease[J]. Chinese Journal of General Practice, 2018, 16(12): 2035-2038. doi: 10.16766/j.cnki.issn.1674-4152.000555
|
[16] |
TAJBAKHSH A, BIANCONI V, PIRRO M, et al. Efferocytosis and atherosclerosis: regulation of phagocyte function by microRNAs[J]. Trends Endocrinol Metab, 2019, 30(9): 672-683. doi: 10.1016/j.tem.2019.07.006
|
[17] |
DORAN A C, YURDAGUL A J, TABAS I. Efferocytosis in health and disease[J]. Nat Rev Immunol, 2020, 20(4): 254-267. doi: 10.1038/s41577-019-0240-6
|
[18] |
LUMBROSO D, SOBOH S, MAIMON A, et al. Macrophage-derived protein S facilitates apoptotic polymorphonuclear cell clearance by resolution phase macrophages and supports their reprogramming[J]. Front Immunol, 2018, 9: 358. doi: 10.3389/fimmu.2018.00358
|
[19] |
CAI B, KASIKARA C, DORAN A C, et al. MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity[J]. Sci Signal, 2018, 11(549): eaar3721. DOI: 10.1126/scisignal.aar3721.
|
[20] |
YURDAGUL A J, DORAN A C, CAI B, et al. Mechanisms and consequences of defective efferocytosis in atherosclerosis[J]. Front Cardiovasc Med, 2018, 4: 86. doi: 10.3389/fcvm.2017.00086
|
[21] |
BOTEANU R M, SUICA V I, UYY E, et al. Alarmins in chronic noncommunicable diseases: atherosclerosis, diabetes and cancer[J]. J Proteomics, 2017, 153: 21-29. doi: 10.1016/j.jprot.2016.11.006
|
[22] |
CHAZAUD B. Inflammation and skeletal muscle regeneration: leave it to the macrophages![J]. Trends Immunol, 2020, 41(6): 481-492. doi: 10.1016/j.it.2020.04.006
|
[23] |
REN J, BI Y, SOWERS J R, et al. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases[J]. Nat Rev Cardiol, 2021, 18(7): 499-521.
|
[24] |
LIN P, JI H H, LI Y J, et al. Macrophage Plasticity and Atherosclerosis Therapy[J]. Front Mol Biosci, 2021, 8: 679797. DOI: 10.3389/fmolb.2021.679797.
|
[25] |
KOJIMA Y, DOWNING K, KUNDU R, et al. Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis[J]. J Clin Invest, 2019, 129(5): 2164. doi: 10.1172/JCI129277
|
[26] |
MOORE K J, TABAS I. Macrophages in the pathogenesis of atherosclerosis[J]. Cell, 2011, 145(3): 341-355. doi: 10.1016/j.cell.2011.04.005
|
[27] |
MARTINET W, SCHRIJVERS D M, DE MEYER G R. Necrotic cell death in atherosclerosis[J]. Basic Res Cardiol, 2011, 106(5): 749-760. doi: 10.1007/s00395-011-0192-x
|
[28] |
JIN Y, LIU Y, XU L, et al. Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis[J]. Cell Death Dis, 2022, 13(5): 512. doi: 10.1038/s41419-022-04966-8
|
[29] |
MARTINET W, COORNAERT I, PUYLAERT P, et al. Macrophage death as a pharmacological target in atherosclerosis[J]. Front Pharmacol, 2019, 10: 306. doi: 10.3389/fphar.2019.00306
|
[30] |
RAYMOND M H, DAVIDSON A J, SHEN Y, et al. Live cell tracking of macrophage efferocytosis during Drosophila embryo development in vivo[J]. Science, 2022, 375(6585): 1182-1187. doi: 10.1126/science.abl4430
|